Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
| 50.05 | |
| 49.73 | |
| - | |
| 50.48 | |
| 49.88 | |
| 37.65-67.8 | |
| 890 M | |
| 12.5062 | |
| 17 657 K | |
| 60 800 K | |
| 0 | |
| 0.795 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100% on a really good stock. Long term Formycon AG (ETR:F...
Formycon AG's (ETR:FYB) price-to-sales (or "P/S") ratio of 13.2x might make it look like a strong sell right now compared to the Biotechs industry in Germany, where around half of the companies have P...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
